BioSpace News Archive

Equillium, Inc. today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.

Acasti Pharma Inc. today announced Jan D’alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.

Today, LCMC Health announced a $1.5 million gift to Xavier University of Louisiana to create and retain a diverse physician workforce in Louisiana.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees.

PDS Biotechnology Corporation today announced that its management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference being held virtually on January 18-19, 2023.

AnaptysBio, Inc. today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share.

Hospital for Special Surgery has appointed experienced healthcare leader, Tara M. McCoy, to the new position of HSS Florida Chief Executive Officer.

First Wave BioPharma, Inc. announced that the U.S. Food and Drug Administration is reviewing the Investigational New Drug amendment for the planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis as an IND protocol amendment.

Lipogems, a clinical stage- global medical technology company, announces the first patient enrolled on January 13, 2023, in the ARISE U.S. FDA IDE study, which aims to examine MicroFat versus corticosteroid injection for the treatment of Knee Osteoarthritis (OA).

Regulus Therapeutics Inc. announced the grant of an inducement stock option to Claire Padgett, Ph.D. and to Rekha Garg, M.D., M.S., on January 11, 2023 in connection with their respective appointments as Regulus’ Senior Vice President, Clinical Operations and Senior Vice President, Clinical Development and Regulatory.